Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights.

To the editor: Chimeric-antigen receptor T-cell (CART-cell) immunotherapy has proven clinical efficacy,[1][1] particularly in B-cell leukemia and lymphoma.[2][2][⇓][3]-[4][4] However, it causes a unique set of toxicities, the foremost of which is cytokine release syndrome (CRS).[5][5],[6][6] The

[1]  S. Rose-John.  The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation , 2017, Clinical pharmacology and therapeutics.

[2]  J. Kochenderfer,et al.  Toxicities of chimeric antigen receptor T cells: recognition and management. , 2016, Blood.

[3]  G. Wertheim,et al.  Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. , 2016, Cancer discovery.

[4]  D. Munn,et al.  IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. , 2016, Trends in immunology.

[5]  M. Kalos,et al.  The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma , 2016, Clinical Cancer Research.

[6]  Bent K Jakobsen,et al.  Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  David L Porter,et al.  CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. , 2015, Blood.

[8]  C. June,et al.  Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies , 2015, Immunological reviews.

[9]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[10]  D. Bartlett,et al.  Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity , 2014, Front. Oncol..

[11]  D. Teachey,et al.  Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies , 2014, Cancer journal.

[12]  Yongmin Tang,et al.  Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. , 2014, Cancer letters.

[13]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[14]  Adam Bagg,et al.  Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. , 2013, Blood.

[15]  A. Eggermont,et al.  Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  W. Wick,et al.  Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. , 2012, Cancer research.

[17]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[18]  C. June,et al.  Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms , 2017, Leukemia.